Abstract: The present application relates to a compound which may be useful for mediating NO production and improving L-arginine bioavailability in a subject. Pharmaceutical compositions comprising the compound and methods of using the compound are also provided.
Abstract: The present disclosure is directed to tetrahydroquinazoline derivatives of Formula I and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV naïve cells, and for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).
Type:
Grant
Filed:
August 25, 2021
Date of Patent:
May 16, 2023
Assignee:
Merck Sharp & Dohme LLC
Inventors:
Antonella Converso, Abdellatif El Marrouni, Anthony W. Shaw, David N. Hunter, Ashley Forster, Cheng Wang, Yunlong Zhang
Abstract: The invention relates to an aqueous pharmaceutical composition comprising: a) bilastine or a pharmaceutically acceptable salt or solvate thereof, b) mometasone, or a pharmaceutically acceptable derivative thereof, c) a suspending agent, and d) 2-hydroxypropyl-?-cyclodextrin; wherein the pH of the aqueous pharmaceutical composition is between 3.5 and 5.5, and wherein the content of 2-hydroxypropyl-?-cyclodextrin is less than 8.5% by weight. The invention also relates to said compositions for use in the treatment and/or prevention of a disorder or disease susceptible to amelioration by antagonism of H1 histamine receptor and/or of a corticosteroid-responsive disease through nasal administration. The invention also relates to a process for preparing the aqueous pharmaceutical composition above mentioned.
Type:
Grant
Filed:
October 15, 2018
Date of Patent:
May 9, 2023
Assignee:
FAES FARMA, S.A.
Inventors:
Gonzalo Hernández Herrero, Ana Gonzalo Gorostiza, Neftalí García Domínguez, Arturo Zazpe Arce, Pablo Morán Poladura, Tania González García
Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and their use for the treatment of cancer.
Abstract: The present invention relates to Rucaparib and/or Talazoparib and/or Veliparib and/or Olaparib, and/or AZD 2461, or a pharmaceutically acceptable salt thereof, for use in the treatment of impaired skin wound healing in a subject, an in vitro method for identifying a subject suffering from impaired skin wound healing to be responsive to the treatment with Rucaparib and/or Talazoparib and/or Veliparib and/or Olaparib and/or AZD 2461, and kits and kits-of-part related thereto.
Type:
Grant
Filed:
April 24, 2018
Date of Patent:
May 2, 2023
Assignee:
AKRIBES BIOMEDICAL GMBH
Inventors:
Barbara Wolff-Winiski, Anton Stütz, Petra Dörfler
Abstract: Compounds, pharmaceutically acceptable salts, esters, prodrugs, and pharmaceutical compositions thereof are disclosed that are useful for inhibition of the biological activity of CCL5 on mammalian cells, as well as methods of treatment for diseases involving the increased biological activity of CCL5.
Abstract: Nasal formulations of metoclopramide, which remain stable and/or colorless upon storage over a period of time, are provided. Also provided are methods of treating disorders treatable with metoclopramide, comprising administering the nasal solutions to patients in need thereof.
Type:
Grant
Filed:
November 20, 2020
Date of Patent:
April 18, 2023
Assignee:
Evoke Pharma, Inc.
Inventors:
Matthew J. D'Onofrio, David A. Gonyer, Shirish A. Shah, Stuart J. Madden
Abstract: Disclosed herein are methods, pharmaceutical combinations, or kits for the prevention or treatment of extrapyramidal syndromes, for example, dyskinesia, dystonia, akathisia, or drug-induced Parkinsonism, with the administration of a therapeutic effective amount of Trapidil, a derivative, a metabolite, a prodrug, an analog, or a pharmaceutically acceptable salt thereof.
Abstract: The present invention provides compounds and intermediates. The present invention also provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation. The present invention also provides compounds that may be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.
Type:
Grant
Filed:
November 24, 2020
Date of Patent:
April 11, 2023
Assignee:
C4 Therapeutics, Inc.
Inventors:
Christopher G. Nasveschuk, Fabian Dey, Annick Goergler, Roger Norcross, Philipp Schmid
Abstract: A leather-like hybrid mycelial cellulose sheet and production thereof. Precise selection of mushroom species and reagents allows for production at low pH, thereby resulting in a strong, flexible, and dry leather-like material suitable for application in various industries.
Type:
Grant
Filed:
May 24, 2022
Date of Patent:
April 11, 2023
Assignee:
VU MON TECHNICAL AND TECHNOLOGY CO., LTD.
Abstract: This invention relates to oral care compositions comprising an effective amount of a basic amino acid in free or salt form, together with an antibacterial agent, and to methods of using and of making such compositions.
Type:
Grant
Filed:
March 28, 2008
Date of Patent:
March 28, 2023
Assignee:
Colgate-Palmolive Company
Inventors:
Michael Prencipe, Ravi Subramanyam, Sarita V. Mello, Donghui Wu, Suman Chopra, Andre M. Morgan, Diane Cummins, Richard J. Sullivan, Ralph Peter Santarpia, III, Lynette Zaidel, Qin Wang, Gary Edward Tambs, Virginia Monsul Barnes, Rajnish Kohli, Richard Scott Robinson, Sergio Leite, Eric A. Simon
Abstract: Methods and kits for treating oral mucositis are disclosed. The treatment comprises administering to a patient in need thereof a Reactive Oxygen Species scavenger in a pharmaceutically acceptable formulation.
Type:
Grant
Filed:
February 27, 2020
Date of Patent:
March 28, 2023
Assignee:
galera labs, llc
Inventors:
David M. Rothstein, Chris Murphy, Vivien Wong, Glenn Kazo
Abstract: Compositions and methods are described for the prevention, treatment, or management of sexual dysfunction, such as premature ejaculation. The method comprises administering an effective amount of tetrahydropalmatine or its derivative or Rhizoma Corydalis extract containing composition to a human male on an as-needed basis shortly before sexual activity to delay ejaculation.
Abstract: Methods for treating cancer and/or inducing tumor regression in mammals (e.g., humans) by increasing the metabolism of the mammal, administering a BA dye to the mammal, and thereafter exposing the tumor to actinic light for activation of the BA dye.
Abstract: A method for manufacturing an insecticidal compound and insecticidal compositions comprising the insecticidal compound and methods of use are presented herein. The manufacturing method presented herein allows for a high purity grade of thiocyclam hydrochloride to be synthesized. The insecticidal compositions comprising the thiocyclam hydrochloride can be used for prevention of crop destruction by insects. The use of thiocyclam hydrochloride in insecticidal compositions as described herein can achieve greater efficacy than previously known insecticides, by eliminating the insect pests more reliably and efficiently.
Type:
Grant
Filed:
March 4, 2020
Date of Patent:
February 28, 2023
Assignee:
ARYSTA LIFESCIENCE NORTH AMERICA, LLC
Inventors:
Cameron S. Gibb, Christopher L. Larson, Mark T. Singleton, Kamal L. Kataria, Samantha Besse, Joseph A. Moore, III, Thomas C. Lovelace, Chandra S. Kanugala, Srinivas Vollala, Balraju Vadla
Abstract: The present disclosure discloses a composition for relieving skin itch or irritation, which contains thymol trimethoxycinnamate or a stereoisomer, salt, hydrate or solvate thereof as an active ingredient, and a method for relieving skin itch or skin irritation by administering the composition to a subject in need of reliving of skin itch or irritation. The composition according to an aspect of the present disclosure has a superior effect of relieving skin itch or skin irritation by inhibiting the voltage-gated sodium channel Nav1.7 without side effects.
Abstract: Methods are provided for treating a subject having a MYC-driven neoplasia. Aspects of the methods include administering to the subject an amount of an inhibitor of a target gene effective to treat the subject for the MYC-driven neoplasia. Methods are also provided for identifying a MYC-dependent target gene in a MYC-driven neoplasia. Aspects of the method include identifying the MYC-dependent target gene based on a phenotype detected in a first tumor cell line conditionally expressing MYC that is absent or quantitatively different in a second tumor cell line conditionally repressing MYC when the two cell lines are contacted with a CRISPR-based gene silencing agent. Kits and cell lines for practicing the methods of the disclosure are also provided.
Type:
Grant
Filed:
January 3, 2018
Date of Patent:
February 14, 2023
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
Anja Deutzmann, Dean W. Felsher, Yulin Li
Abstract: Novel NTRK1 fusion molecules, detection reagents, and uses and kits for evaluating, identifying, assessing and/or treating a subject having a cancer are disclosed.
Type:
Grant
Filed:
November 14, 2019
Date of Patent:
February 14, 2023
Assignee:
Foundation Medicine, Inc.
Inventors:
Matthew J. Hawryluk, Doron Lipson, Vincent A. Miller, Philip James Stephens